Cited by 280Cancer Immunotherapy and BiomarkersImmunotherapy and Immune ResponsesT-cell and B-cell Immunology

The DOI matches its Crossref record; 96 of the 97 references it cites were found in a registry or an index.

Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

Open access

Pauken, Kristen E., Dougan, Michael, Rose, Noel R., Lichtman, Andrew H., Sharpe, Arlene H.·2019·Trends in Immunology

DOI 10.1016/j.it.2019.04.002PMC PMC6527345

Open this paper in CoChat — free account

Abstract

Oncology has recently undergone a revolutionary change with widespread adoption of immunotherapy for many cancers. Immunotherapy using monoclonal antibodies against checkpoint molecules, including programmed death (PD)-1, PD ligand (PD-L)1, and cytotoxic T lymphocyte-associated antigen (CTLA)-4, is effective in a significant subset of patients. However, immune-related adverse events (irAEs) have emerged as frequent complications of checkpoint blockade, likely due to the physiological role of checkpoint pathways in regulating adaptive immunity and preventing autoimmunity. As immunotherapy becomes more common, a better understanding of the etiology of irAEs and ways to limit these events is needed. At the same time, studying these new therapy-related disorders provides an opportunity to better understand naturally occurring human autoimmune and inflammatory disorders, with the potential to improve therapies for cancer and autoimmune diseases.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1016/j.it.2019.04.002

Cites

96 of 96 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,989
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay‐Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,320
Improved Survival with Ipilimumab in Patients with Metastatic Melanoma
Hodi, F. S., O'Day, S. J., McDermott, D. F., Weber, R. W., Sosman, J. A., Haanen, J. B., Gonzalez, R., Robert, C., Schadendorf, D., Hassel, J. C., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1003466 · Cited by 15,155
The blockade of immune checkpoints in cancer immunotherapy
Pardoll, D. M. (2012) · Nature Reviews Cancer · doi:10.1038/nrc3239 · Cited by 13,838
Safety, activity, and immune correlates of anti–PD-1 antibody in cancer
Topalian, S. L., Hodi, F. S., Brahmer, J. R., Gettinger, S. N., Smith, D. C., McDermott, D. F., Powderly, J. D., Carvajal, R. D., Sosman, J. A., Atkins, M. B., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1200690 · Cited by 12,628
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency
Le, D. T., Uram, J. N., Wang, H., Bartlett, B. R., Kemberling, H., Eyring, A. D., Skora, A. D., Luber, B. S., Azad, N. S., Laheru, D., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1500596 · Cited by 9,377
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
Larkin, J., Chiarion-Sileni, V., Gonzalez, R., Grob, J. J., Cowey, C. L., Lao, C. D., Schadendorf, D., Dummer, R., Smylie, M., Rutkowski, P., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504030 · Cited by 8,157
Cancer immunotherapy using checkpoint blockade
Ribas, A., & Wolchok, J. D. (2018) · Science · doi:10.1126/science.aar4060 · Cited by 6,791
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Tumeh, P. C., Harview, C. L., Yearley, J. H., Shintaku, I. P., Taylor, E. J. M., Robert, L., Chmielowski, B., Spasic, M., Henry, G., Ciobanu, V., et al. (2014) · Nature · doi:10.1038/nature13954 · Cited by 6,609
Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer
Garon, E. B., Rizvi, N. A., Hui, R., Leighl, N., Balmanoukian, A. S., Eder, J. P., Patnaik, A., Aggarwal, C., Gubens, M., Horn, L., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1501824 · Cited by 6,198

Show all 97 references

Sorted by citations

Hallmarks of response, resistance, and toxicity to immune checkpoint blockade
Morad, G., Helmink, B. A., Sharma, P., & Wargo, J. A. (2021) · Cell · doi:10.1016/j.cell.2021.09.020 · Cited by 1,648
Immune-related adverse events of checkpoint inhibitors
Ramos‐Casals, M., Brahmer, J. R., Callahan, M. K., Flores-Chávez, A., Keegan, N. M., Khamashta, M. A., Lambotte, O., Mariette, X., Prat, A., & Suarez-Almazor, M. E. (2020) · Nature Reviews Disease Primers · doi:10.1038/s41572-020-0160-6 · Cited by 1,491
Manganese is critical for antitumor immune responses via cGAS-STING and improves the efficacy of clinical immunotherapy
Lv, M., Chen, M., Zhang, R., Zhang, W., Wang, C., Zhang, Y., Wei, X., Guan, Y., Liu, J., Feng, K., et al. (2020) · Cell Research · doi:10.1038/s41422-020-00395-4 · Cited by 1,040
Immune checkpoint therapy for solid tumours: clinical dilemmas and future trends
Sun, Q., Hong, Z., Zhang, C., Wang, L., Han, Z., & Ma, D. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01522-4 · Cited by 598
ImmunoPET: Concept, Design, and Applications
Wei, W., Rosenkrans, Z. T., Liu, J., Huang, G., Luo, Q., & Cai, W. (2020) · Chemical Reviews · doi:10.1021/acs.chemrev.9b00738 · Cited by 504
T Cell Exhaustion
Baessler, A., & Vignali, D. A. A. (2024) · Annual Review of Immunology · doi:10.1146/annurev-immunol-090222-110914 · Cited by 420
Immunologic tumor microenvironment modulators for turning cold tumors hot
Khosravi, G. R., Mostafavi, S., Bastan, S., Ebrahimi, N., Gharibvand, R. S., & Eskandari, N. (2024) · 癌症：英文版 · doi:10.1002/cac2.12539 · Cited by 403
Understanding and treating the inflammatory adverse events of cancer immunotherapy
Dougan, M., Luoma, A. M., Dougan, S. K., & Wucherpfennig, K. W. (2021) · Cell · doi:10.1016/j.cell.2021.02.011 · Cited by 319
Self-citation
AGA Clinical Practice Update on Diagnosis and Management of Immune Checkpoint Inhibitor Colitis and Hepatitis: Expert Review
Dougan, M. L., Wang, Y., Rubio‐Tapia, A., & Lim, J. K. (2020) · Gastroenterology · doi:10.1053/j.gastro.2020.08.063 · Cited by 298
Self-citation
Immune-related toxicities of checkpoint inhibitors: mechanisms and mitigation strategies
Sullivan, R. J., & Weber, J. S. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-021-00259-5 · Cited by 312
Immune mechanisms of toxicity from checkpoint inhibitors
Wang, S. J., Dougan, S. K., & Dougan, M. L. (2023) · Trends in cancer · doi:10.1016/j.trecan.2023.04.002 · Cited by 313
Self-citation
Emerging photodynamic nanotherapeutics for inducing immunogenic cell death and potentiating cancer immunotherapy
Zhang, S., Wang, J., Kong, Z., Sun, X., He, Z., Sun, B., Luo, C., & Sun, J. (2022) · Biomaterials · doi:10.1016/j.biomaterials.2022.121433 · Cited by 261
Biological drug and drug delivery-mediated immunotherapy
Xiao, Q., Li, X., Li, Y., Wu, Z., Xu, C., Chen, Z., & He, W. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.12.018 · Cited by 221
Targeting Treg cells with GITR activation alleviates resistance to immunotherapy in murine glioblastomas
Amoozgar, Z., Kloepper, J., Ren, J. P., Tay, R. E., Kazer, S. W., Kiner, E., Krishnan, S., Posada, J. M., Ghosh, M., Mamessier, É., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-22885-8 · Cited by 200
Incidence rates of immune-related adverse events and their correlation with response in advanced solid tumours treated with NIVO or NIVO+IPI: a systematic review and meta-analysis
Xing, P., Zhang, F., Wang, G., Xu, Y., Li, C., Wang, S., Guo, Y., Cai, S., Wang, Y., & Li, J. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0779-6 · Cited by 181
Gel/hydrogel‐based in situ biomaterial platforms for cancer postoperative treatment and recovery
Feng, Y., Zhang, Z., Tang, W., & Dai, Y. (2023) · Exploration · doi:10.1002/exp.20220173 · Cited by 175
Immune escape: A critical hallmark in solid tumors
Mortezaee, K. (2020) · Life Sciences · doi:10.1016/j.lfs.2020.118110 · Cited by 162
Targeting Negative and Positive Immune Checkpoints with Monoclonal Antibodies in Therapy of Cancer
Marhelava, K., Pilch, Z., Bajor, M., Graczyk‐Jarzynka, A., & Zagożdżon, R. (2019) · Cancers · doi:10.3390/cancers11111756 · Cited by 159
Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
Badran, Y. R., Cohen, J. V., Brastianos, P. K., Parikh, A. R., Hong, T. S., & Dougan, M. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0711-0 · Cited by 143
Self-citation
Photothermal-Chemotherapy Integrated Nanoparticles with Tumor Microenvironment Response Enhanced the Induction of Immunogenic Cell Death for Colorectal Cancer Efficient Treatment
Wen, Y., Chen, X., Zhu, X., Gong, Y., Yuan, G., Qin, X., & Liu, J. (2019) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.9b17137 · Cited by 133
Immune‐related adverse events in the gastrointestinal tract: diagnostic utility of upper gastrointestinal biopsies
Zhang, M. L., Neyaz, A., Patil, D. T., Chen, J. H., Dougan, M. L., & Deshpande, V. (2019) · Histopathology · doi:10.1111/his.13963 · Cited by 113
Self-citation
Autoreactive CD8+ T cells are restrained by an exhaustion-like program that is maintained by LAG3
Grebinoski, S., Zhang, Q., Cillo, A. R., Manne, S., Xiao, H., Brunazzi, E. A., Tabib, T., Cardello, C., Lian, C. G., Murphy, G. F., et al. (2022) · Nature Immunology · doi:10.1038/s41590-022-01210-5 · Cited by 107
Tissue-Resident Memory T Cells Mediate Immune Homeostasis in the Human Pancreas Through the PD-1/PD-L1 Pathway
Weisberg, S. P., Carpenter, D. J., Chait, M., Dogra, P., Gartrell, R. D., Chen, A., Campbell, S., Liu, W., Saraf, P., Snyder, M. E., et al. (2019) · Cell Reports · doi:10.1016/j.celrep.2019.11.056 · Cited by 104
Control of Lymphocyte Fate, Infection, and Tumor Immunity by TCF-1
Raghu, D., Xue, H., & Mielke, L. A. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.10.006 · Cited by 98
Budesonide treatment for microscopic colitis from immune checkpoint inhibitors
Hughes, M. S., Molina, G. E., Chen, S. T., Zheng, H., Deshpande, V., Fadden, R. M., Sullivan, R. J., & Dougan, M. L. (2019) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-019-0756-0 · Cited by 100
Self-citation
In Situ Formed Fibrin Scaffold with Cyclophosphamide to Synergize with Immune Checkpoint Blockade for Inhibition of Cancer Recurrence after Surgery
Zhang, L., Zhou, J., Hu, L., Han, X., Zou, X., Chen, Q., Chen, Y., Liu, Z., & Wang, C. (2019) · Advanced Functional Materials · doi:10.1002/adfm.201906922 · Cited by 95
How to manage patients with corticosteroids in oncology in the era of immunotherapy?
Aldea, M. D., Orillard, É., Mansi, L., Marabelle, A., Scotté, F., Lambotte, O., & Michot, J. (2020) · European Journal of Cancer · doi:10.1016/j.ejca.2020.09.032 · Cited by 96
DNA Nanostructure as an Efficient Drug Delivery Platform for Immunotherapy
Chi, Q., Yang, Z., Xu, K., Wang, C., & Liang, H. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01585 · Cited by 88
Resident Kupffer cells and neutrophils drive liver toxicity in cancer immunotherapy
Siwicki, M. R., Gort-Freitas, N. A., Messemaker, M., Bill, R., Gungabeesoon, J., Engblom, C., Žilionis, R., Garris, C., Gerhard, G. M., Kohl, A., et al. (2021) · Science Immunology · doi:10.1126/sciimmunol.abi7083 · Cited by 89
Eliciting anti-cancer immunity by genetically engineered multifunctional exosomes
Cheng, Q., Dai, Z., Smbatyan, G., Epstein, A. L., Lenz, H., & Zhang, Y. (2022) · Molecular Therapy · doi:10.1016/j.ymthe.2022.06.013 · Cited by 90
Liver biopsy findings in patients on immune checkpoint inhibitors
Cohen, J. V., Dougan, M. L., Zubiri, L., Reynolds, K. L., Sullivan, R. J., & Misdraji, J. (2020) · Modern Pathology · doi:10.1038/s41379-020-00653-1 · Cited by 89
Self-citation
Blockade of novel immune checkpoints and new therapeutic combinations to boost antitumor immunity
Archilla‐Ortega, A., Domuro, C., Martín-Liberal, J., & Muñoz, P. (2022) · Journal of Experimental & Clinical Cancer Research · doi:10.1186/s13046-022-02264-x · Cited by 79
Tumor immune microenvironment modulation-based drug delivery strategies for cancer immunotherapy
Han, S., Huang, K., Gu, Z., & Wu, J. (2019) · Nanoscale · doi:10.1039/c9nr08086d · Cited by 85
Impact of Glucocorticoid Use in Oncology in the Immunotherapy Era
Kalfeist, L., Galland, L., Ledys, F., Ghiringhelli, F., Limagne, E., & Ladoire, S. (2022) · Cells · doi:10.3390/cells11050770 · Cited by 78
Mucosal inflammation predicts response to systemic steroids in immune checkpoint inhibitor colitis
Mooradian, M. J., Wang, D. Y., Coromilas, A. J., Lumish, M. A., Chen, T., Giobbie‐Hurder, A., Johnson, D. B., Sullivan, R. J., & Dougan, M. L. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000451 · Cited by 76
Self-citation
Vitamin D intake is associated with decreased risk of immune checkpoint inhibitor‐induced colitis
Grover, S., Dougan, M. L., Tyan, K., Giobbie‐Hurder, A., Blum, S. M., Ishizuka, J. J., Qazi, T., Elias, R., Vora, K. B., Ruan, A. B., et al. (2020) · Cancer · doi:10.1002/cncr.32966 · Cited by 77
Self-citation
Checkpoint inhibitor hepatotoxicity: pathogenesis and management
Cunningham, M. E., Gupta, R., & Butler, M. O. (2023) · Hepatology · doi:10.1097/hep.0000000000000045 · Cited by 75
Immune checkpoint receptors in autoimmunity
Burke, K. P., Patterson, D. G., Liang, D., & Sharpe, A. H. (2023) · Current Opinion in Immunology · doi:10.1016/j.coi.2023.102283 · Cited by 70
Self-citation
Metabolic regulation by PD-1 signaling promotes long-lived quiescent CD8 T cell memory in mice
Kalia, V., Yuzefpolskiy, Y., Vegaraju, A., Xiao, H., Baumann, F. M., Jatav, S., Church, C. D., Prlic, M., Jha, A., Nghiem, P., et al. (2021) · Science Translational Medicine · doi:10.1126/scitranslmed.aba6006 · Cited by 71
Emerging nanotherapeutics for antithrombotic treatment
Zhao, Z., Yang, F., Zhang, X., Sun, J., He, Z., & Luo, C. (2020) · Biomaterials · doi:10.1016/j.biomaterials.2020.120200 · Cited by 68
Immune checkpoint inhibitor-associated celiac disease
Badran, Y. R., Shih, A. R., Leet, D., Mooradian, M. J., Coromilas, A. J., Chen, J. H., Kem, M., Zheng, H., Borowsky, J., Misdraji, J., et al. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2020-000958 · Cited by 68
Self-citation
Endogenous Stimuli‐Activatable Nanomedicine for Immune Theranostics for Cancer
Wang, W., Jin, Y., Liu, X., Chen, F., Zheng, X., Liu, T., Yang, Y., & Yu, H. (2021) · Advanced Functional Materials · doi:10.1002/adfm.202100386 · Cited by 66
Improving cancer treatments via dynamical biophysical models
Kuznetsov, M. B., Clairambault, J., & Volpert, V. A. (2021) · Physics of Life Reviews · doi:10.1016/j.plrev.2021.10.001 · Cited by 64
Inhibitory receptor agonists: the future of autoimmune disease therapeutics?
Grebinoski, S., & Vignali, D. A. (2020) · Current Opinion in Immunology · doi:10.1016/j.coi.2020.06.001 · Cited by 58
Diagnosis and Management of Immune Checkpoint Inhibitor Colitis.
Hashash, J. G., Francis, F. F., & Farraye, F. A. (2021) · Europe PMC (PubMed Central) · Cited by 55
Adverse Events of Concurrent Immune Checkpoint Inhibitors and Antiangiogenic Agents: A Systematic Review
Gao, L., Yang, X., Cheng, Y., & Zhu, H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01173 · Cited by 57
Immune-related serious adverse events with immune checkpoint inhibitors: Systematic review and network meta-analysis
Oliveira, C., Mainoli, B., Duarte, G. S., Machado, T. L. G. N., Tinoco, R. G., Esperança‐Martins, M., Ferreira, J. J., & Costa, J. N. (2024) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-024-03647-z · Cited by 53
Multinational Association of Supportive Care in Cancer (MASCC) 2020 clinical practice recommendations for the management of severe gastrointestinal and hepatic toxicities from checkpoint inhibitors
Dougan, M. L., Blidner, A. G., Choi, J. N., Cooksley, T., Glezerman, I. G., Ginex, P., Girotra, M., Gupta, D., Johnson, D. B., Shannon, V. R., et al. (2020) · Supportive Care in Cancer · doi:10.1007/s00520-020-05707-3 · Cited by 53
Self-citation
Activation pathways that drive CD4 + T cells to break tolerance in autoimmune diseases*
Krovi, S. H., & Kuchroo, V. K. (2022) · Immunological Reviews · doi:10.1111/imr.13071 · Cited by 56
Host Immune Response Triggered by Graphene Quantum-Dot-Mediated Photodynamic Therapy for Oral Squamous Cell Carcinoma
Zhang, X., Li, H., Yi, C., Chen, G., Li, Y., Zhou, Y., Chen, G., Li, Y., He, Y., & Yu, D. (2020) · International Journal of Nanomedicine · doi:10.2147/ijn.s276153 · Cited by 51
Immunosuppressive Nanoparticles for Management of Immune-Related Adverse Events in Liver
Shen, S., Dai, H., Fei, Z., Chai, Y., Hao, Y., Fan, Q., Dong, Z., Zhu, Y., Xu, J., Ma, Q., et al. (2021) · ACS Nano · doi:10.1021/acsnano.1c02391 · Cited by 52
Understanding adverse events of immunotherapy: A mechanistic perspective
Burke, K. P., Grebinoski, S., Sharpe, A. H., & Vignali, D. A. A. (2020) · The Journal of Experimental Medicine · doi:10.1084/jem.20192179 · Cited by 47
Self-citation
Neoantigen-specific CD4 + T-cell response is critical for the therapeutic efficacy of cryo-thermal therapy
Peng, P., Hu, H., Liu, P., & Xu, L. X. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000421 · Cited by 49
New Approaches to Targeting B Cells for Myasthenia Gravis Therapy
Huda, R. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.00240 · Cited by 53
Epithelial Ovarian Cancer and the Immune System: Biology, Interactions, Challenges and Potential Advances for Immunotherapy
Macpherson, A. M., Barry, S. C., Ricciardelli, C., & Oehler, M. K. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9092967 · Cited by 51
Identification of a Small-Molecule Inhibitor That Disrupts the SIX1/EYA2 Complex, EMT, and Metastasis
Zhou, H., Blevins, M. A., Hsu, J. Y., Kong, D., Galbraith, M. D., Goodspeed, A. E., Culp‐Hill, R., Oliphant, M. U. J., Ramirez, D. A., Zhang, L., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0435 · Cited by 46
Systematic review of immune checkpoint inhibitor-related gastrointestinal, hepatobiliary, and pancreatic adverse events
Shatila, M., Zhang, H. C., Thomas, A. S., Machado, A. P., Naz, S., Mittal, N., Catinis, C., Varatharajalu, K., Cruz, C. C., Lu, E., et al. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009742 · Cited by 45
Nanomaterials-Mediated Immunomodulation for Cancer Therapeutics
Jindal, A., Sarkar, S., & Alam, A. (2021) · Frontiers in Chemistry · doi:10.3389/fchem.2021.629635 · Cited by 42
Systematic comparison with autoimmune liver disease identifies specific histological features of immune checkpoint inhibitor-related adverse events
Coukos, A., Vionnet, J., Obéid, M., Bouchaab, H., Peters, S., Latifyan, S., Wicky, A. M., Michielin, O. A., Chtioui, H., Moradpour, D., et al. (2022) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2022-005635 · Cited by 43
Polygenic risk score for ulcerative colitis predicts immune checkpoint inhibitor-mediated colitis
Middha, P., Thummalapalli, R., Betti, M. J., Yao, L., Quandt, Z., Balaratnam, K., Bejan, C. A., Cardenas, E. R., Falcon, C. J., Faleck, D. M., et al. (2024) · Nature Communications · doi:10.1038/s41467-023-44512-4 · Cited by 42
Immune Checkpoint Inhibitor Toxicity in Head and Neck Cancer: From Identification to Management
Wang, H., Mustafa, A., Liu, S., Liu, J., Lv, D., Yang, H. J., & Zou, J. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.01254 · Cited by 41
Advances and clinical applications of immune checkpoint inhibitors in hematological malignancies
Sun, W., Hu, S., & Wang, X. (2024) · 癌症：英文版 · doi:10.1002/cac2.12587 · Cited by 42
Targeting PGLYRP1 promotes antitumor immunity while inhibiting autoimmune neuroinflammation
Schnell, A., Huang, L., Regan, B. M. L., Singh, V., Vonficht, D., Bollhagen, A., Wang, M., Hou, Y., Bod, L., Sobel, R. A., et al. (2023) · Nature Immunology · doi:10.1038/s41590-023-01645-4 · Cited by 39
The Anticancer Potential of Apigenin Via Immunoregulation
Xu, L., Zaky, M. Y., Yousuf, W., Ullah, A., Abdelbaset, G. R., Zhang, Y., Ahmed, O. M., Liu, S., & Liu, H. (2020) · Current Pharmaceutical Design · doi:10.2174/1381612826666200713171137 · Cited by 40
Improved Immunotherapy for Gastric Cancer by Nanocomposites with Capability of Triggering Dual-Damage of Nuclear/Mitochondrial DNA and Cgas/Sting-Mediated Innate Immunity
Guo, W., Chen, Z., Li, Z., Huang, H., Ren, Y., Zhao, B., Li, G., & Hu, Y. (2022) · Chemical Engineering Journal · doi:10.1016/j.cej.2022.136428 · Cited by 38
Uncoupling Therapeutic Efficacy from Immune-Related Adverse Events in Immune Checkpoint Blockade
Hu, W., Wang, G., Wang, Y., Riese, M. J., & You, M. (2020) · iScience · doi:10.1016/j.isci.2020.101580 · Cited by 35
Single-cell profiling reveals unique features of diabetogenic T cells in anti-PD-1-induced type 1 diabetes mice
Collier, J. L., Pauken, K. E., Lee, C. A. A., Patterson, D. G., Markson, S. C., Conway, T. S., Fung, M. E., France, J. A., Mucciarone, K., Lian, C. G., et al. (2023) · The Journal of Experimental Medicine · doi:10.1084/jem.20221920 · Cited by 33
Self-citation
Colitis after checkpoint blockade: a retrospective cohort study of melanoma patients requiring admission for symptom control
Hughes, M. S., Zheng, H., Zubiri, L., Molina, G. E., Chen, S. T., Mooradian, M. J., Allen, I. M., Reynolds, K. L., & Dougan, M. (2019) · Cancer Medicine · doi:10.1002/cam4.2397 · Cited by 32
Self-citation
Gastrointestinal and Hepatic Complications of Immunotherapy: Current Management and Future Perspectives
Dougan, M. L. (2020) · Current Gastroenterology Reports · doi:10.1007/s11894-020-0752-z · Cited by 33
Self-citation
A case of dual-mechanism immune-related anaemia in a patient with metastatic melanoma treated with nivolumab and ipilimumab
Olson, D. J., Rajagopal, P. S., Tjota, M. Y., Venkataraman, G., Luke, J. J., & Gajewski, T. F. (2020) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2019-000380 · Cited by 31
Immune-Related Adverse Events Induced by Immune Checkpoint Inhibitors and CAR-T Cell Therapy: A Comprehensive Imaging-Based Review
Pozzessere, C., Mazini, B., Omoumi, P., Jreige, M., Noirez, L., Digklia, A., Fasquelle, F., Sempoux, C. L., & Dromain, C. (2024) · Cancers · doi:10.3390/cancers16142585 · Cited by 32
Blockade of innate inflammatory cytokines TNFα, IL-1β, or IL-6 overcomes virotherapy-induced cancer equilibrium to promote tumor regression
Walsh, M. J., Ali, L. R., Lenehan, P. J., Kureshi, C. T. S., Kureshi, R., Dougan, M. L., Knipe, D. M., & Dougan, S. K. (2023) · Immunotherapy Advances · doi:10.1093/immadv/ltad011 · Cited by 29
Self-citation
Prophylactic IL-23 blockade uncouples efficacy and toxicity in dual CTLA-4 and PD-1 immunotherapy
Ju, M., Zhang, J., Deng, Z., Wei, M., Ma, L., Chen, T., & Lin, Z. (2024) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2024-009345 · Cited by 30
Anti-Cancer Nanomedicines: A Revolution of Tumor Immunotherapy
Li, W., Peng, A., Wu, H., Quan, Y., Li, Y., Lu, L., & Cui, M. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.601497 · Cited by 29
Perspectives on Oncolytic Salmonella in Cancer Immunotherapy—A Promising Strategy
Wang, D., Wei, X., Kalvakolanu, D. V., Guo, B., & Zhang, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.615930 · Cited by 29
Concurrent immune checkpoint inhibition and selective immunosuppressive therapy in patients with immune-related enterocolitis
Badran, Y. R., Zou, F., Durbin, S., Dutra, B. E., Abu‐Sbeih, H., Thomas, A. S., Altan, M., Thompson, J. A., Qiao, W., Leet, D., et al. (2023) · Journal for ImmunoTherapy of Cancer · doi:10.1136/jitc-2023-007195 · Cited by 29
Self-citation
Neurotransmitters: an emerging target for therapeutic resistance to tumor immune checkpoint inhibitors
Yang, J., Wu, Y., Lv, X., Liu, S., Yuan, Z., Chen, Y., Ding, X., Zhong, L., & Wang, X. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02413-8 · Cited by 30
Research progress on immunotherapy in triple‑negative breast cancer (Review)
Zhang, X., Ge, X., Jiang, T., Yang, R., & Li, S. (2022) · International Journal of Oncology · doi:10.3892/ijo.2022.5385 · Cited by 28
IFNγ is a central node of cancer immune equilibrium
Walsh, M. J., Stump, C. T., Kureshi, R., Lenehan, P. J., Ali, L. R., Dougan, M. L., Knipe, D. M., & Dougan, S. K. (2023) · Cell Reports · doi:10.1016/j.celrep.2023.112219 · Cited by 28
Self-citation
Integrative analyses of bulk and single-cell RNA-seq identified cancer-associated fibroblasts-related signature as a prognostic factor for immunotherapy in NSCLC
Wang, S., Fan, G., Li, L., He, Y., Lou, N., Xie, T., Dai, L., Gao, R., Yang, M., Shi, Y., et al. (2023) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-023-03428-0 · Cited by 28
Pharmacological Activation of Estrogen Receptor Beta Overcomes Tumor Resistance to Immune Checkpoint Blockade Therapy
Huang, S., Zhou, N., Zhao, L., Gimple, R. C., Ahn, Y. H., Zhang, P., Wang, W., Shao, B., Yang, H. J., Zhang, Q., et al. (2020) · iScience · doi:10.1016/j.isci.2020.101458 · Cited by 28
Improvement of PD-1 Blockade Efficacy and Elimination of Immune-Related Gastrointestinal Adverse Effect by mTOR Inhibitor
Bai, X., Wang, X., Ma, G., Song, J., Liu, X., Wu, X. L., Zhao, Y., Liu, X., Liu, Z., Zhang, W., et al. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.793831 · Cited by 27
Association Between Immune-Related Adverse Events and Clinical Outcomes to Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Blockade in SCLC
Ricciuti, B., Naqash, A. R., Naidoo, J., Sehgal, K., Miller, A. R., Kehl, K. L., Venkatraman, D., Sands, J. M., Lamberti, G., Recondo, G., et al. (2020) · JTO Clinical and Research Reports · doi:10.1016/j.jtocrr.2020.100074 · Cited by 25
Injectable Liquid Crystal Formation System for Reshaping Tumor Immunosuppressive Microenvironment to Boost Antitumor Immunity: Postoperative Chemoimmunotherapy
Hu, M. Y., Zhang, J., Yu, Y., Tu, K., Yang, T., Wang, Y., Hu, Q., Kong, L., & Zhang, Z. (2020) · Small · doi:10.1002/smll.202004905 · Cited by 26
Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment
Knisely, A. T., Seo, Y. D., Wargo, J. A., & Chelvanambi, M. (2023) · Cancers · doi:10.3390/cancers15030777 · Cited by 26
Immune‐related adverse events in non‐small cell lung cancer: Occurrence, mechanisms and therapeutic strategies
Lin, X., Xie, M., Yao, J., Ma, X., Lin, Q., Zhang, X., Song, J., Bao, X., Zhang, X., Zhang, Y., et al. (2024) · Clinical and Translational Medicine · doi:10.1002/ctm2.1613 · Cited by 24
S1PR1-biased activation drives the resolution of endothelial dysfunction-associated inflammatory diseases by maintaining endothelial integrity
Zheng, H., Yu, J., Gao, L., Wang, K., Xu, Z., Zeng, Z., Zheng, K., Tang, X., Tian, X., Zhao, Q., et al. (2025) · Nature Communications · doi:10.1038/s41467-025-57124-x · Cited by 26
Non-invasive Detection of Immunotherapy-Induced Adverse Events
Ferreira, C. A., Heidari, P., Ataeinia, B., Sinevici, N., Sise, M. E., Colvin, R. B., Wehrenberg-Klee, E. P., & Mahmood, U. (2021) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-20-4641 · Cited by 24
Histopathology of Gastrointestinal Immune-related Adverse Events
Zhang, M. L., & Deshpande, V. (2021) · The American Journal of Surgical Pathology · doi:10.1097/pas.0000000000001730 · Cited by 24
Immune-Related Adverse Events of the Gastrointestinal System
Nicolaides, S., & Boussioutas, A. (2023) · Cancers · doi:10.3390/cancers15030691 · Cited by 24
Graphdiyne Oxide-Mediated Photodynamic Therapy Boosts Enhancive T-Cell Immune Responses by Increasing Cellular Stiffness
Zhang, L., Pan, K., Huang, S., Zhang, X., Zhu, X., He, Y., Chen, X., Tang, Y., Yuan, L., & Yu, D. (2023) · International Journal of Nanomedicine · doi:10.2147/ijn.s392998 · Cited by 24
Steering and controlling evolution — from bioengineering to fighting pathogens
Lässig, M., Mustonen, V., & Nourmohammad, A. (2023) · Nature Reviews Genetics · doi:10.1038/s41576-023-00623-8 · Cited by 24
T cell-mediated mechanisms of immune-related adverse events induced by immune checkpoint inhibitors
Li, L., Huang, Y., Xue, R., Li, L., Li, L., Liang, L., Lai, K., Huang, X., Qin, Y., & Zheng, Y. (2025) · Critical Reviews in Oncology/Hematology · doi:10.1016/j.critrevonc.2025.104808 · Cited by 25
Baseline neutrophil-lymphocyte ratio and platelet-lymphocyte ratio appear predictive of immune treatment related toxicity in hepatocellular carcinoma
Dharmapuri, S., Özbek, U., Jethra, H., Jun, T. W., Marron, T. U., Saeed, A., Huang, Y., Muzaffar, M., Pinter, M., Balcar, L., et al. (2023) · World Journal of Gastrointestinal Oncology · doi:10.4251/wjgo.v15.i11.1900 · Cited by 26
Demystifying phytoconstituent-derived nanomedicines in their immunoregulatory and therapeutic roles in inflammatory diseases
Chen, F., & Liu, Q. (2022) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2022.114317 · Cited by 24
CD8+ Lymphocyte Infiltration Is a Specific Feature of Colitis Induced by Immune Checkpoint Inhibitors
Takahashi, Y., Nagaya, T., Iwaya, Y., Okamura, T., Hirayama, A., Iwaya, M., Uehara, T., & Umemura, T. (2022) · Digestive Diseases and Sciences · doi:10.1007/s10620-022-07598-2 · Cited by 21
Novel endoscopic scoring system for immune mediated colitis: a multicenter retrospective study of 674 patients
Wang, Y., Abu‐Sbeih, H., Tang, T., Shatila, M., Faleck, D. M., Harris, J., Dougan, M. L., Olsson-Brown, A. C., Johnson, D. B., Shi, C., et al. (2024) · Gastrointestinal Endoscopy · doi:10.1016/j.gie.2024.01.024 · Cited by 21
Self-citation
Myeloid Cell-Targeted Nanocarriers Efficiently Inhibit Cellular Inhibitor of Apoptosis for Cancer Immunotherapy
Koch, P. D., Rodell, C. B., Köhler, R. H., Pittet, M. J., & Weissleder, R. (2020) · Cell chemical biology · doi:10.1016/j.chembiol.2019.12.007 · Cited by 21
Cascade-Responsive Hierarchical Nanosystems for Multisite Specific Drug Exposure and Boosted Chemoimmunotherapy
Zhang, J., Zhang, Y., Zhao, B., Lv, M., Chen, E., Zhao, C., Jiang, L., Qian, H., Huang, D., Zhong, Y., et al. (2021) · ACS Applied Materials & Interfaces · doi:10.1021/acsami.1c16636 · Cited by 20
The Safety of Immunosuppressants Used in the Treatment of Immune-Related Adverse Events due to Immune Checkpoint Inhibitors: a Systematic Review
Machado, A. P., Ratliff, H., Abdelwahab, A., Vohra, M. H., Kuang, A., Shatila, M., Khan, M. A., Shafi, M. A., Thomas, A. S., Philpott, J. R., et al. (2023) · Journal of Cancer · doi:10.7150/jca.87335 · Cited by 20

Authors: Pauken, K. E., Dougan, M., Rose, N. R., Lichtman, A. H., & Sharpe, A. H.
Affiliations: Brigham and Women's Hospital (US)
Harvard University (US)
Corresponding author: Lichtman, Andrew H.
Sharpe, Arlene H.
ORCID: Pauken, Kristen E.
Dougan, Michael
Lichtman, Andrew H.
Sharpe, Arlene H.
Venue: Trends in Immunology
Publisher: Elsevier BV
Published: 2019-06
Volume: 40
Issue: 6
Pages: 511-523
ISSN: 1471-4906 (ISSN-L)
DOI: 10.1016/j.it.2019.04.002
PMC: PMC6527345
OpenAlex: W2943668434
Cited by: 280
References: 97
Citations by year: 2026: 24 · 2025: 33 · 2024: 43 · 2023: 46 · 2022: 42 · 2021: 37 · 2020: 40 · 2019: 15
FWCI: 3.19
Type: journal article
Language: en
Open access: bronze
doi.org
Licence: www.elsevier.com/tdm/userlicense/1.0/ (tdm)
www.elsevier.com/legal/tdmrep-license (tdm)
www.elsevier.com/open-access/userlicense/1.0/ (am, 362 d)
Locations: Trends in Immunology (acceptedVersion)
PubMed (publishedVersion)
PubMed Central (acceptedVersion)
Funders: US National Institutes of Health Mentored Clinical Scientist Development Award (1K08DK114563-01)
American Gastroenterological Association Research Scholars Award (HL121363, HL13186)
National Institutes of Health (R01 AI040614, P01 AI056299, AI108545)
Topics: Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
Keywords: immune-related adverse events, cancer immunotherapy, immune checkpoint blockade, PD-1, PD-L1, CTLA-4, monoclonal antibodies, autoimmunity, autoimmune disease therapy
MeSH terms: Antineoplastic Agents, Immunological, Animals, Disease Susceptibility, Humans, Immunotherapy, Neoplasms, Biomarkers, Tumor, Autoimmunity, T-Lymphocyte Subsets, Disease Management, Immunomodulation, Tumor Microenvironment, Patient Outcome Assessment

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Adverse Events Following Cancer Immunotherapy: Obstacles and Opportunities

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Self-check

Citations

Cites

Cited by

Related

Metadata

Record

About these checks